Genmab maps Phase III strategy HuMax-CD20

Denmark's Genmab is laying plans to launch a late-stage study of its closely watched antibody HuMax-CD20 (ofatumumab) as a treatment for rheumatoid arthritis. Licensed by GlaxoSmithKline in a $2.1 billion pact, HuMax-CD20 is also being studied as a potential treatment for blood cancers. The trial will focus on two patient groups, one demonstrating an inadequate response to methotrexate therapy and another group that has had an inadequate response to TNF-alpha antagonist therapy.

"From the data to date, we believe that ofatumumab has real potential," says Genmab CEO Lisa N. Drakeman, Ph.D. "Now that Phase III studies are underway in multiple indications, we are moving closer to realizing this potential and bringing this important treatment to patients."

- take a look at the release for more info

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.